AUPH - Aurinia is up 25% on voclosporin win; expects net revenue at $65K per patient

Aurinia Pharmaceuticals (AUPH) has surged ~24.5% in response to its late Friday announcement of FDA approval for LUPKYNIS (voclosporin) for adults with active lupus nephritis.In a conference call arranged to discuss the regulatory win, the company estimated that the average annualized net revenue from the treatment could be ~$65K per patient after accounting for rebates, channel discounts, and anticipated patient adherence.Considered as a rare disease lupus nephritis affects nearly a third of people diagnosed with systemic lupus erythematosus estimated at ~200 – 300K patients in the U.S. alone.The company has already completed the pre-approval information exchange with more than 50 payers covering two-thirds of commercially insured lives.With the in-person and virtual launch of voclosporin taking place in 2021, Aurinia projects a peak annual U.S. net sales of more than $1B from the therapy.The company has a collaboration and license agreement with Otsuka Pharmaceutical for the development and commercialization of oral voclosporin in countries outside the

For further details see:

Aurinia is up 25% on voclosporin win; expects net revenue at $65K per patient